A randomized, phase 2/3 study comparing BMS-986504 in combination with Nab-paclitaxel and Gemcitabine versus placebo in combination with Nab-paclitaxel and Gemcitabine in participants with untreated metastatic pancreatic ductal adenocarcinoma harboring homozygous MTAP deletion

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522598-12-00

Acronym

CA240-0030

Enrollment

162

Registered

2025-11-28

Start date

2025-12-17

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Brief summary

Time to disease worsening on scans and time to death (Phase 3)

Detailed description

Rate of tumor shrinkage, duration of tumor shrinkage, time to tumor shrinkage, and rate of participants with control of tumor growth and/or shrinkage

Interventions

DRUGMrtx1719 matching placebo

DRUGGEMCITABINE

DRUGPACLITAXEL ALBUMIN-BOUND

DRUGMRTX1719

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to disease worsening on scans and time to death (Phase 3)	—

Secondary

Measure	Time frame
Rate of tumor shrinkage, duration of tumor shrinkage, time to tumor shrinkage, and rate of participants with control of tumor growth and/or shrinkage	—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Romania, Slovakia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026